Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Aug 7;17(1):526.
doi: 10.1186/s12885-017-3521-0.

Pirfenidone as salvage treatment for refractory bleomycin-induced lung injury: a case report of seminoma

Koji Sakamoto  1 , Satoru Ito  2 , Naozumi Hashimoto  3 , Yoshinori Hasegawa  3
Affiliations
Case Reports

Pirfenidone as salvage treatment for refractory bleomycin-induced lung injury: a case report of seminoma

Koji Sakamoto et al. BMC Cancer. .

Abstract

Background: Bleomycin-induced lung injury, a major complication of chemotherapy for germ cell tumors, occasionally fails to respond to the standard treatment with corticosteroids and develops into severe respiratory insufficiency. Little is known about salvage treatment for refractory cases.

Case presentation: A 63-year-old man who had been diagnosed with stage I seminoma and undergone a high orchiectomy 1 year previously developed swelling of his left iliac lymph node and was diagnosed with a recurrence of the seminoma. He was administered a standard chemotherapy regimen of cisplatin, etoposide, and bleomycin. At the end of second cycle, he developed a dry cough and fever that was accompanied by newly-identified bilateral infiltrates on chest X-ray. Despite initiation of oral prednisolone, his exertional dyspnea and decline in pulmonary functions continued to be aggravated. High-dose pulse treatment with methylprednisolone was introduced and improved his symptoms and radiologic findings. However, the maintenance dose of oral prednisolone allowed reactivation of the disease with evidence of newly-developed bilateral lung opacities on high-resolution CT scans. Considering his glucose intolerance and cataracts as complications of corticosteroid treatment, administration of pirfenidone was initiated with the patient's consent. Pirfenidone at 1800 mg/day was well tolerated, and resolved his symptoms and abnormal opacities on a chest CT scan. Subsequently, the dose of prednisolone was gradually tapered without worsening of the disease. At the most recent follow-up, he was still in complete remission of seminoma with a successfully tapered combination dose of prednisolone and pirfenidone.

Conclusions: Pirfenidone, a novel oral agent with anti-inflammatory and -fibrotic properties, should be considered as a salvage drug for refractory cases of bleomycin-induced lung injury.

Keywords: Anti-fibrotic agent; Bleomycin; Lung toxicity; Pirfenidone; Refractory.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The study was approved by the Institutional Review Committee of Nagoya University Hospital (approval number 44).

Consent for publication

Written consent for publication of the case was obtained from the patient.

Competing interests

The authors have no competing interest, including relevant financial interests, activities, and affiliations.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Chest high-resolution CT findings. a Ground glass and dense consolidations with patchy distribution were observed in the bilateral lungs before steroid pulse therapy. b 3 months after steroid pulse therapy, the bilateral dense consolidation seen in (a) was resolved. c 8 months after steroid pulse therapy, newly developed bilateral opacities were seen (arrowheads). d 1 year after the initiation of pirfenidone add-on therapy
See this image and copyright information in PMC

References

    1. Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients eith Hodgkin's lymphoma. J Clin Oncol. 2005;23(30):7614–7620. doi: 10.1200/JCO.2005.02.7243. - DOI - PubMed
    1. O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14(1):91–96. doi: 10.1093/annonc/mdg020. - DOI - PubMed
    1. Azuma A. Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis. Exp Rev Respir Med. 2010;4(3):301–310. doi: 10.1586/ers.10.32. - DOI - PubMed
    1. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med. 1995;125(6):779–785. - PubMed
    1. Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, Matsushima S, Torii M, Arimura A. Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008;590(1–3):400–408. doi: 10.1016/j.ejphar.2008.06.046. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources